Heart failure & cardiomyopathies
Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy
- randomized
- 1:1
- subgroup analysis by geographic region
+2 more
- 1:1
- subgroup analysis by geographic region
Authors' conclusion
In SEQUOIA-HCM, the dosing, safety, and treatment effects of aficamten were consistent across geographic regions despite differences in baseline characteristics of patients with oHCM.
Study context
- Population
- Patients with obstructive HCM (oHCM) in the SEQUOIA-HCM trial, grouped by geographic regionpatients enrolled in 14 countries · Europe, including Israel 142 (50%) · North America 94 (33%) · China 46 (16%)
- Participants
- 282 patients
- Comparison
- Baseline characteristics and treatment effects on peak oxygen uptake (pVO2) and secondary endpoints were compared across geographic groups
Primary result
As reported in the abstract
Age · Baseline
Europe
59.7 years
North America
61.7 years
China
51.8 years
Secondary outcomes
| Outcome | Values |
|---|---|
| NYHA class II · Baseline | Europe 81.7% · China 93.5% · North America 58.5% |
| KCCQ-CSS · Baseline | China 82.4 · Europe 73.1 · North America 73.2 |
Benefit of aficamten on pVO2 by region
- not modified by region
- interaction p=0.88
- The benefit of aficamten on pVO2 was not modified by region (interaction p=0.88); all secondary endpoints improved with aficamten treatment
- the analysis was underpowered to detect regional differences
Original publication
Efficacy of aficamten according to geographic location of patients with hypertrophic obstructive cardiomyopathy. ESC Heart Fail. Published 20 January 2026. doi:10.1093/eschf/xvag023
Summarised from the published abstract; every number is checked against it